Artelo Biosciences Inc   (ARTL)
Other Ticker:  
Price: $1.4500 $0.02 1.137%
Day's High: $1.48 Week Perf: -8.05 %
Day's Low: $ 1.43 30 Day Perf: -1.36 %
Volume (M): 3 52 Wk High: $ 2.98
Volume (M$): $ 4 52 Wk Avg: $1.64
Open: $1.45 52 Wk Low: $1.15

 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Artelo Biosciences Inc
Artelo Biosciences Inc is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics targeting the endocannabinoid system for the treatment of various diseases and conditions. The company focuses on developing drugs that modulate the endocannabinoid system to address pain, inflammation, and cancer-related symptoms. Artelo's pipeline includes candidates for cancer-related anorexia and weight loss, opioid reduction in cancer patients, and arthritis. They aim to provide safe and effective treatment options to improve the lives of patients suffering from these conditions.

   Company Address: 505 Lomas Santa Fe Solana Beach 92075 CA
   Company Phone Number: 925-7049   Stock Exchange / Ticker: NASDAQ ARTL


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Artelo Biosciences Inc

Pharmaceutical Giant Faces Major Financial Setback in Q4 of 2023

Artelo Biosciences Inc, a clinical-stage pharmaceutical company, has experienced some fluctuations in its stock price over the past 30 days. The stock has decreased by -9.52% during this period, but overall, it has seen a 10.14% increase since the beginning of 2024. However, it is important to note that the stock currently trades only 32.2% above its 52-week low.
In terms of financial performance, Artelo Biosciences Inc reported an operating deficit of $-3.24 million for the fourth quarter of 2023. This indicates that the company spent more money on its operations than it earned during this period. However, it is worth mentioning that the company has become more cost-effective compared to the same time frame in the previous year, when it had an operating deficit of $-3.476 million.

Clinical Study

Breakthrough Pre-Clinical Research Reveals Artelo Biosciences' ART26.12 as Promising Treatment for Oxaliplatin-Induced Peripheral Neuropathy

Published Tue, Jan 23 2024 1:30 PM UTC

Artelo Biosciences, a clinical-stage pharmaceutical company specializing in modulating lipid-signaling pathways, has recently published new pre-clinical research demonstrating the effectiveness of its asset, ART26.12, in treating and preventing Oxaliplatin-Induced Peripheral Neuropathy (OIPN). This ground-breaking discovery has significant implications for individuals living...

Clinical Study

Artelo Biosciences Strategically Aligns with Worldwide Clinical Trials to Propel First-In-Human Study of ART26.12

Published Mon, Jan 8 2024 1:30 PM UTC

In a landmark development, Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company committed to the propagation of lipid-signaling pathways to cultivate treatments for cancer, neuropathic pain, and neurological disorders, has disclosed its association with Worldwide Clinical Trials. The latter is recognized as a global, award-winning contract research...

Artelo Biosciences Inc

Artelo Biosciences Inc Reveals Worsening Financial Performance in Q3 2023 Amidst Growing Operating Deficit

Artelo Biosciences Inc is a company operating in the Major Pharmaceutical Preparations sector that recently disclosed an operating deficit of $-2.614 million for the most recent fiscal period from July to September 30, 2023. This information holds significance as it allows us to make comparisons and understand the financial health and progress of the company.
When comparing these results with the third quarter of 2022, we can see that the operating deficit has increased from $-2.394 million to $-2.614 million. This indicates that the company's financial performance has worsened during this period.
Despite the growing deficit, it is important to note that the CEO of Artelo Biosciences Inc is actively pursuing various business models to ensure a constant product line. This suggests that the company is working towards improving its financial situation and exploring different strategies to generate revenue.

Artelo Biosciences Inc

Artelo Biosciences Inc Attracts Attention with Significant Financial Improvement, Reporting Reduced Operating Deficit of $-1.784 Million in Q2 2023

As the Major Pharmaceutical Preparations industry continues to evolve, several lesser-known entities are starting to gain attention with their financial results. One such company, Artelo Biosciences Inc (ARTL), recently announced its financial performance for the second quarter of 2023. This article aims to interpret these results and discuss how they might impact the company going forward.
1. Reduced Operating Deficit:
ARTL's second-quarter financial report showcased a significant improvement in its operating deficit compared to the same period the previous year. The company reported an operating deficit of $-1.784 million, demonstrating a more economically competitive edge compared to the operating deficit of $-2.471 million in the comparable period of 2022.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com